Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 29, 2024 11:15 ET | Source: Research and Markets

Levofloxacin Market Forecast Reveals Rapid Growth in Asia-Pacific Region and Advancements in Targeted Therapies

Dublin, Jan. 29, 2024 (GLOBE NEWSWIRE) -- The "Levofloxacin Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. Global attention turns to the recent...
May 28, 2023 06:00 ET | Source: REPORTSINSIGHTS CONSULTING PVT LTD

Pyelonephritis Treatment Market Worth US$ 351.35 Mn By 2030, A Survey By Reports Insights

New York, May 28, 2023 (GLOBE NEWSWIRE) -- According to a recent report by Reports Insights, the Pyelonephritis treatment market is poised for strong expansion and is expected to reach USD 351.35...
April 27, 2023 04:58 ET | Source: Research and Markets

Global Antibiotics Market Report 2023: Growing Development Pipeline and Positive Clinical Trial Results Bode Well for Industry

Dublin, April 27, 2023 (GLOBE NEWSWIRE) -- The "Global Antibiotics Market - Distribution by Type of Drug Class, Target Disease Indication, Type of Therapy (Monotherapies and Combination Therapies),...
July 01, 2021 07:03 ET | Source: Research and Markets

China Levofloxacin Market Report 2021: CAGR of Sales Value is -4.75% from 2016 to 2020 - Forecasts to 2025

Dublin, July 01, 2021 (GLOBE NEWSWIRE) -- The "Investigation Report on China's Levofloxacin Market 2021-2025" report has been added to ResearchAndMarkets.com's offering. Levofloxacin, developed by...
February 09, 2021 04:38 ET | Source: Research and Markets

Global Urinary Tract Infection Treatment Markets, 2020-2027 - Market for Penicillin and Combination Drugs Segment to Grow at Highest Rate

Dublin, Feb. 09, 2021 (GLOBE NEWSWIRE) -- The "Urinary Tract Infection Treatment Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Drug Class, Indication, Distribution Channel, and...
April 11, 2016 07:05 ET | Source: Raptor Pharmaceutical Inc

Raptor Pharmaceutical Launches QUINSAIR™ in Europe

NOVATO, Calif., April 11, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced its first commercial sale of QUINSAIR™ (levofloxacin inhalation solution) in Germany and...
August 20, 2015 17:16 ET | Source: Raptor Pharmaceutical Inc

Raptor Pharmaceutical Corp. Expands Rare Disease Portfolio With the Acquisition of Quinsair(TM)

First Inhaled Fluoroquinolone Therapy for Patients with Cystic Fibrosis Approval Received in the European Union and Canada Expansion of Pipeline with Multiple Late-Stage Orphan Indication...
July 13, 2015 03:53 ET | Source: Persistence Market Research

U.S Bacterial Conjunctivitis Drugs Market Will Reach US& 439.8 Million in 2024 by Persistence Market Research

New York, July 13, 2015 (GLOBE NEWSWIRE) -- According to a new market report published by Persistence Market Research "The U.S Market Study on Bacterial Conjunctivitis Drugs: fluoroquinolones to be...